Evidence map›Paper›PMID 40645456›Full record

ArticleThe Journal of infection2025

Bordetella pertussis infection and antibody dynamics in household cohorts in two South African communities, 2016 - 2018: findings from the PHIRST study.

Fahima Moosa, Jackie Kleynhans, Lillian Makhathini, Mignon du Plessis, Stefano Tempia, Meredith L McMorrow, Jocelyn Moyes, Amelia Buys, Lorens Maake, Sheilagh Smit and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Fahima MoosaCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: fahimam@nicd.ac.za.
Jackie KleynhansCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Lillian MakhathiniCentre for Vaccines and Immunology, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Mignon du PlessisCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Stefano TempiaCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, United States of America; Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa; MassGenics, Duluth, GA, United States of America.
Meredith L McMorrowInfluenza Division, Centers for Disease Control and Prevention, Atlanta, GA, United States of America; Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Jocelyn MoyesCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Amelia BuysCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Lorens MaakeCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Sheilagh SmitCentre for Vaccines and Immunology, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Neil A MartinsonPerinatal HIV Research Unit, MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, South Africa; DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, University of the Witwatersrand, Johannesburg, South Africa; Johns Hopkins University Center for TB Research, Baltimore, MD, United States of America.
Kathleen KahnMRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; Epidemiology and Global Health Unit, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Limakatso LebinaPerinatal HIV Research Unit, MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, South Africa.
Cheryl CohenCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Anne von GottbergCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Nicole WolterCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Funding

Southern African-Pittsburgh Public Health Genomic Epidemiology Training Program (SAPPHGenE)D43TW011255 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Lee H Harrison, Anne von Gottberg · 2019 to 2026
$1.7M
FIC NIH HHS D43 TW011255Intramural CDC HHS CC999999NCIRD CDC HHS U51 IP000155
6 · The paper itself

Abstract

INTRODUCTION AND

methodsIn a cohort study, enrolling new households annually during 2016-2018, we estimated the B. pertussis attack rate using serology and PCR, identified factors associated with seroconversion, and described antibody changes over time. Nasopharyngeal swabs were collected biweekly for 6-10 months annually, with cases defined as individuals testing PCR-positive at least once. Seroconversion was defined as a ≥4-fold increase in anti-pertussis toxin IgG concentration between consecutive blood draws. Logistic regression was used to identify factors associated with seroconversion among PCR-positive individuals.

resultsAmong 1509 participants, the serology attack rate was 5.8% (87/1509), 6.2% (94/1509) by PCR, and 9.6% (145/1509) combining both methods. Among PCR-positive cases, 38.3% (36/94) seroconverted, with a mean time to seroconversion of 2.9 months (range: 3 weeks-5.9 months). Younger participants (5-18 years) (adjusted odds ratio (aOR) 6.8, 95% confidence interval (CI) 1.3-35.1) and those with episode durations of ≥7 days (aOR 13.3, 95% CI 3.4-51.1) were more likely to seroconvert. Among the seroconverted, 75.0% (27/36) maintained antibody concentrations >40 IU/ml for at least 12 months post-infection. DISCUSSION: Almost 10% of participants had B. pertussis infection during follow-up. Less than half of individuals with PCR-confirmed infection seroconverted but maintained elevated antibodies for at least one-year post-infection.

Indexed as

Antibodies, BacterialBordetella pertussisWhooping CoughAdolescentAdultChildChild, PreschoolCohort StudiesFamily CharacteristicsFemaleHumansImmunoglobulin GInfantMaleMiddle AgedNasopharynxAntibodies, BacterialImmunoglobulin GPertussis ToxinAntibodiesAntibody dynamicsAnti-PT IgGB. pertussisELISAReal-time PCRSeroconversion

Identifiers

PMID40645456
PMCPMC12477660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.